Document Detail

Liposomal Fasudil, a Rho-Kinase Inhibitor, for Prolonged Pulmonary Preferential Vasodilation in Pulmonary Arterial Hypertension.
MedLine Citation:
PMID:  23353807     Owner:  NLM     Status:  Publisher    
Current pharmacological interventions for pulmonary arterial hypertension (PAH) require continuous infusions, multiple inhalations, or oral administration of drugs that act on various pathways involved in the pathogenesis of PAH. However, invasive methods of administration, short duration of action, and lack of pulmonary selectivity result in noncompliance and poor patient outcomes. In this study, we tested the hypothesis that encapsulation of an investigational anti-PAH molecule fasudil (HA-1077), a Rho-kinase inhibitor, into liposomal vesicles results in prolonged vasodilation in distal pulmonary arterioles. Liposomes were prepared by hydration and extrusion method and fasudil was loaded by ammonium sulfate-induced transmembrane electrochemical gradient. Liposomes were then characterized for various physicochemical properties. Optimized formulations were tested for pulmonary absorption and their pharmacological efficacy in a monocrotaline (MCT) induced rat model of PAH. The entrapment efficiency of optimized liposomal fasudil formulations was between 68.1±0.8% and 73.6±2.3%, and the cumulative release at 37°C was 98-99% over a period of 5days. Compared to intravenous (IV) fasudil, a ~10 fold increase in the terminal plasma half-life was observed when liposomal fasudil was administered as aerosols. The t(1/2) of IV fasudil was 0.39±0.12h. and when given as liposomes via pulmonary route, the t(1/2) extended to 4.71±0.72h. One h after intratracheal instillation of liposomal fasudil, mean pulmonary arterial pressure (MPAP) was reduced by 37.6±5.7% and continued to decrease for about 3h, suggesting that liposomal formulations produced pulmonary preferential vasodilation in MCT induced PAH rats. Overall, this study established the proof-of-principle that aerosolized liposomal fasudil is a feasible option for a non-invasive, controlled release and pulmonary preferential treatment of PAH.
Vivek Gupta; Nilesh Gupta; Imam H Shaik; Reza Mehvar; Ivan F McMurtry; Masahiko Oka; Eva Nozik-Grayck; Masanobu Komatsu; Fakhrul Ahsan
Related Documents :
18681927 - Ultrasound velocity criteria for vertebral origin stenosis.
675497 - Decompression of vertebral artery in cases of cervical spondylosis.
20609807 - Resection of apical lung carcinoma involving the vertebral artery.
23892097 - L-cysteine ethyl ester reverses the deleterious effects of morphine on, arterial blood-...
3986487 - Asymptomatic carotid stenosis: is prophylactic endarterectomy justifiable?
3044267 - Mitral valve prolapse--a review.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-23
Journal Detail:
Title:  Journal of controlled release : official journal of the Controlled Release Society     Volume:  -     ISSN:  1873-4995     ISO Abbreviation:  J Control Release     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8607908     Medline TA:  J Control Release     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012. Published by Elsevier B.V.
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, 1300S Coulter, Amarillo, TX - 79106, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multifunctional Terpolymeric MRI Contrast Agent with Superior Signal Enhancement in Blood and Tumor.
Next Document:  Silica-Lipid Hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: A...